Impact Of Physiotherapy And Botox In Improving Functional Outcomes Among Post Stroke Focal Dystonia Patients
Impact Of Physiotherapy And Botulinum Toxin Type-A In Improving Functional Outcomes In Upper Limb Focal Dystonia Among Post Stroke Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients having first episode of unilateral stroke
- At least 6 months of post stroke duration presenting with post stroke focal dystonia of the upper limb.
- No previous exposure of the affected hand of Botox.
- Reduced upper limb functions
- Both genders will be included equally.
Exclusion Criteria:
- Significant speech or cognitive impairment which impedes the ability to perform the assessment.
- Other significant upper limb impairment e.g. fracture or frozen shoulder within 6 months.
- Severe arthritis, amputation, evidence of fixed contracture, pregnancy or lactating womens.
- Other diagnosis likely to interfere with rehabilitation or outcome assessments, e.g. blind, malignancy,
- Other conditions which may contribute to upper limb spasticity, e.g. multiple sclerosis, cerebral palsy.
- Use of botulinum toxin to the upper limb in the previous 4 months.
- Contraindications to intramuscular injection.
- Contraindications /allergy to botulinum toxin type A, which include bleeding disorders, myasthenia gravis and concurrent use of aminoglycosides.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Experimental Group
The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients.
It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
|
All patients in the experimental group received a BoNT-A injection.
The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available).
The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
Task specific training is the repetition of a specific task until expertise is reached.
More challenging tasks are added as a means of progression
|
|
PLACEBO_COMPARATOR: Control Group
The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
|
Task specific training is the repetition of a specific task until expertise is reached.
More challenging tasks are added as a means of progression
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Action Research Arm Test (ARAT):
Time Frame: 12 weeks
|
It assessed specific changes in limb function by 19 items grouped in four subscales.
The total score ranged from 0 to 57.
The lower score indicated no movement and upper score indicated normal performance of the patient.
|
12 weeks
|
|
MOTOR ASSESSMENT SCALE (MAS)
Time Frame: 12 weeks
|
It was a performance-based scale, based on a task-oriented approach to evaluate and assesses performance of functional tasks rather than isolated patterns of movement.
All items were assessed using a 7-point scale from 0 - 6.
A score of 6 indicated optimal motor behavior.
|
12 weeks
|
|
WOLF MOTOR FUNCTION TEST (WMFT)
Time Frame: 12 weeks
|
It quantified motor ability through timed functional tasks.
It used a 6-point ordinal scale with "0" = "does not attempt with the involved arm" to "5" = movement appears to be normal."
|
12 weeks
|
|
FUGL- MEYER ASSESSMENT TEST
Time Frame: 12 weeks
|
It was a performance-based impairment index to measure motor functioning.
The total score possible was from 0 - 66, with higher function showing the improved level of independence
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severity Of Dystonia
Time Frame: 12 weeks
|
The Arm Dystonia Disability Scale: The severity of dystonia was assessed using 0 (None) to 3 (Marked Difficulty in performing activity
|
12 weeks
|
|
Stroke Specific Quality Of Life
Time Frame: 12 weeks
|
The stroke specific Quality Of Life was administered to patients which rated their Quality of life
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesias
- Dystonia
- Dystonic Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
Other Study ID Numbers
- IIRS-IUISB/PHD/008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.